文献速递其他结缔组织病

尼达尼布治疗系统性硬化相关间质性肺病的疗效预测因素及长期安全性:意大利多中心研究

Predictors of response and long-term efficacy and safety of nintedanib in systemic sclerosis-interstitial lung disease: data from an Italian multicentre study.
PubMed 文献 · Semin Arthritis Rheum · 2026-10-21

该回顾性多中心队列纳入151例符合2013 ACR/EULAR分类标准的SSc-ILD患者,评估尼达尼布真实世界疗效与安全性。启动尼达尼布后12个月内肺功能保持稳定,进展比例较前一年下降(65% vs 25%,p<0.001),合并MMF使用与较低进展风险相关(OR 0.318,95%CI 0.104-0.973)。胃肠道不耐受是剂量调整主因,需高剂量PPI预测剂量减少/停药(OR 3.643,95%CI 1.206-11.003)。

要点

  • 尼达尼布启动后12个月内肺功能保持稳定,进展比例较前一年显著下降。
  • 合并使用MMF与较低的肺进展风险相关(OR 0.318)。
  • 需高剂量PPI预测尼达尼布剂量减少或停药(OR 3.643)。

核心结论

  • 在真实世界队列中,启动尼达尼布后至24个月肺功能下降减缓,支持其在常规诊疗中的有效性。

研究设计与样本

  • 回顾性观察性研究,纳入意大利13个三级中心的151例符合2013 ACR/EULAR分类标准的SSc-ILD患者,启动尼达尼布治疗。

主要发现

  • 启动尼达尼布前一年%pFVC从75±19降至70±20(p<0.001),%pDLCO从49±18降至45±17(p<0.001)。
  • 启动后12个月%pFVC为71±18至72±18%(p=0.290),%pDLCO为44±16至44±15%(p=0.646),无显著变化。
  • 启动后达到进展定义的比例低于前一年(25% vs 65%,p<0.001)。
  • 合并MMF使用与较低进展风险相关(OR 0.318,95%CI 0.104-0.973)。
  • 37%需剂量减少,17%停药;需高剂量PPI预测剂量减少/停药(OR 3.643,95%CI 1.206-11.003)。

关键数值与推荐

  • 肺进展定义为以下≥2项:%pFVC下降≥5、%pDLCO下降≥10、HRCT进展或呼吸症状恶化。
  • 患者69%女性,平均年龄60±11.9岁,48%弥漫型、42%局限型皮肤型SSc,89%接受背景免疫抑制,79.3%使用MMF。

临床怎么用

  • 尼达尼布可用于SSc-ILD常规治疗以减缓肺功能下降,合并MMF可能获益更多。
  • 胃肠道不耐受常见,需高剂量PPI者更易减量或停药,应加强监测与管理。

局限性

  • 回顾性观察性设计,24个月随访仅42例,存在选择偏倚与混杂可能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the real-life efficacy and safety of nintedanib (NTD) in systemic sclerosis-associated interstitial lung disease (SSc-ILD) and to identify predictors of lung function progression and treatment discontinuation in a large Italian multicentre cohort. METHODS: This retrospective observational study included SSc-ILD patients from 13 Italian tertiary centres who fulfilled 2013 ACR/EULAR classification criteria and initiated NTD. Clinical data were collected 12 months prior to NTD initiation, at baseline, and after 12 and 24 months. Lung progression was defined by ≥2 of the following: decline ≥5 predicted forced vital capacity (%pFVC), ≥10 predicted diffusing capacity for carbon monoxide (%pDLCO), progression on HRCT, or worsening respiratory symptoms. Logistic regression analyses were performed to identify predictors of lung progression and NTD dose reduction/discontinuation. RESULTS: A total of 151 patients were included (69% female, mean age 60±11.9 years), 48% with diffuse and 42% with limited cutaneous SSc. Most patients (89%) received background immunosuppression, predominantly mycophenolate mofetil (MMF, 79.3%). Before nintedanib initiation, mean FVC % predicted and DLCO % predicted declined (%pFVC 75 ± 19 to 70 ± 20, p < 0.001; %pDLCO from 49 ± 18 to 45 ± 17, p < 0.001), whereas no statistically significant mean change was observed during the first 12 months after initiation (%pFVC 71 ± 18 to 72 ± 18%, p = 0.290; %pDLCO 44 ± 16 to 44 ± 15%, p = 0.646). The proportion meeting progression definition was lower after initiation than during the preceding year (65%vs 25%, p < 0.001). Concomitant MMF use was associated with lower odds of progression (OR 0.318, 95%CI 0.104-0.973). Gastrointestinal intolerance was the main cause of NTD regimen modification: 37% required dose reduction while 17% discontinued the treatment. The need for high-dose proton pump inhibitors predicted NTD dose reduction/discontinuation (OR 3.643, 95%CI 1.206-11.003). At 24 months (n = 42), lung function remained stable (%pFVC 68 ± 19 versus 69 ± 18, p = 0.725; %pDLCO 39 ± 17 versus 43 ± 19, p = 0.065) without any new safety issue. CONCLUSION: In this real-world cohort, initiation of nintedanib was followed by attenuation of pulmonary function decline through 24 months among patients with available follow-up. These findings are supportive of nintedanib effectiveness in routine care.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Campochiaro C, Benfaremo D, De Luca G, et al. Predictors of response and long-term efficacy and safety of nintedanib in systemic sclerosis-interstitial lung disease: data from an Italian multicentre study. Semin Arthritis Rheum. 2026. PMID: 42945827. doi:10.1016/j.semarthrit.2026.153091

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。